Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Original Article
  • Published:

Allografting

CD8+ T-cell-depleted, matched unrelated donor, allogeneic bone marrow transplantation for advanced AML using busulfan-based preparative regimens

Summary:

The role of T-cell depletion (TCD) to prevent graft-versus-host disease (GVHD) after matched unrelated donor allogeneic bone marrow transplant (MUD BMT) remains undefined. Most studies employ total body irradiation and pan TCD. Between March 1993 and June 2002, we treated 33 relapsed acute myelogenous leukemia (AML) patients with busulfan-based preparative regimens and selective TCD. The preparative regimen consisted of busulfan 14 mg/kg, cyclophosphamide 120 mg/kg and VP-16 50 mg/kg in all but one patient who only received busulfan and cyclophosphamide. Donor marrow was depleted of CD8+ T cells by immunomagnetic bead separation. The patients were also treated with cyclosporine and methylprednisolone or FK-506 and mini-dose methotrexate. Four (15%) of 33 patients developed graft failure or rejection. However, three of these patients were serologically mismatched at HLA-Cw. Although 67% of evaluable patients developed acute GVHD, severe grade III–IV acute GVHD only developed in 19%. The severity of acute GVHD correlated with the degree of CD8+ TCD. Median relapse-free survival was 5 months among 20 patients treated with active AML, and 28 months among 13 patients treated in complete remission. Our results confirm that MUD BMT with CD8+ TCD for AML is a potentially curative treatment option.

This is a preview of subscription content, access via your institution

Access options

Rent or buy this article

Prices vary by article type

from$1.95

to$39.95

Prices may be subject to local taxes which are calculated during checkout

Figure 1

Similar content being viewed by others

References

  1. Ferrara JLM, Deeg HJ . Graft-versus-host disease. N Engl J Med 1991; 324: 667–674.

    Article  CAS  PubMed  Google Scholar 

  2. Kernan NA, Bartsch G, Ash RC et al. Analysis of 462 transplantations from unrelated donors facilitated by the National Marrow Donor Program. N Engl J Med 1993; 328: 593–602.

    Article  CAS  PubMed  Google Scholar 

  3. Champlin R . T-cell depletion to prevent graft-versus-host disease after bone marrow transplantation. Hematol/Oncol Clin N Am 1990; 4: 687–698.

    Article  CAS  Google Scholar 

  4. Marmont AM, Horowitz MM, Gale RP et al. T-cell depletion of HLA-identical transplants in leukemia. Blood 1991; 78: 2120–2130.

    CAS  PubMed  Google Scholar 

  5. Butturini A, Gale RP . Graft versus leukemia in humans. Cancer Treat Res 1995; 76: 299–314.

    Article  CAS  PubMed  Google Scholar 

  6. Kernan NA, Bordignon C, Heller G et al. Graft failure after T-cell-depleted human leukocyte antigen identical marrow transplants for leukemia: I. Analysis of risk factors and results of secondary transplants. Blood 1989; 74: 2227–2236.

    CAS  PubMed  Google Scholar 

  7. Kroger N, Zabelina T, Kruger W et al. Comparison of total body irradiation vs busulfan in combination with cyclophosphamide as conditioning for unrelated stem cell transplantation in CML patients. Bone Marrow Transplant 2001; 27: 349–354.

    Article  CAS  PubMed  Google Scholar 

  8. Klein JL, Avalos BR, Belt P et al. Bone marrow engraftment following unrelated donor transplantation utilizing busulfan and cyclophosphamide preparatory chemotherapy. Bone Marrow Transplant 1996; 17: 479–483.

    CAS  PubMed  Google Scholar 

  9. Bertz H, Potthoff K, Mertelsmann R, Finke J . Busulfan/cyclophosphamide in volunteer unrelated donor (VUD) BMT: excellent feasibility and low incidence of treatment-related toxicity. Bone Marrow Transplant 1997; 19: 1169–1173.

    Article  CAS  PubMed  Google Scholar 

  10. Champlin R, Ho W, Gajewski J et al. Selective depletion of CD8+ T lymphocytes for prevention of graft-versus-host disease after allogeneic bone marrow transplantation. Blood 1990; 76: 418–423.

    CAS  PubMed  Google Scholar 

  11. Jansen J, Hanks S, Akard L et al. Selective T cell depletion with CD8-conjugated magnetic beads in the prevention of graft-versus-host disease after allogeneic bone marrow transplantation. Bone Marrow Transplant 1995; 9: 271–278.

    Google Scholar 

  12. Nimer SD, Giorgi J, Gajewski JL et al. Selective depletion of CD8+ cells for prevention of graft-versus-host disease after bone marrow transplantation: a randomized trial. Transplant 1994; 57: 82–87.

    Article  CAS  Google Scholar 

  13. Tutschka PJ, Copelan EA, Klein JP . Bone marrow transplantation for leukemia following a new busulfan and cyclophosphamide regimen. Blood 1987; 70: 1382–1388.

    CAS  PubMed  Google Scholar 

  14. Sahebi F, Copelan E, Crilley P et al. Unrelated allogeneic bone marrow transplantation using high-dose busulfan and cyclophosphamide (BU-CY) for the preparative regimen. Bone Marrow Transplant 1996; 17: 685–689.

    CAS  PubMed  Google Scholar 

  15. Paul P, Apgar J, Ball EJ . HLA-DRB1* intron-primed sequencing for haploid genotyping. Clin Chem 2003; 49: 692–694.

    Article  CAS  PubMed  Google Scholar 

  16. Fernandez-Vina MA, Bignon JD . Primers and oligonucleotide probes (SSOP) used for DNA typing of HLA class II alleles. In: Genetic diversity of HLA: functional and medical implication. In: Charron D (ed.). Genetic Diversity of HLA: Functional and Medical Implication. EDK: Sevres, FR, 1997; pp 596–632.

    Google Scholar 

  17. Kimura A, Sasazuki T . Eleventh International Histocompatibility Workshop reference protocol for the HLA-DNA-typing technique. In: Tsuji K, Aizawa M, Sasazuki T (eds). Eleventh International Histocompatibility Workshop and Conference; 1992 November 6–13, 1991, Yokohoma, Japan Oxford University Press: Oxford, UK, 1992; pp 397–419.

    Google Scholar 

  18. Paul P, Apgar P, Cook D, Ball EJ . Characterization of a new HLA-C allele: Cw*0719. Tissue Antigens 2004; 63: 602–605.

    Article  CAS  PubMed  Google Scholar 

  19. Petersdorf EW, Longton GM, Anasetti C et al. The significance of HLA-DRβ1 matching on clinical outcome after HLA-A, B, DR identical unrelated donor marrow transplantation. Blood 1995; 86: 1606–1613.

    CAS  PubMed  Google Scholar 

  20. Sierra J, Storer B, Hansen JA et al. Unrelated donor marrow transplantation for acute myeloid leukemia: an update of the Seattle experience. Bone Marrow Transplant 2000; 26: 397–404.

    Article  CAS  PubMed  Google Scholar 

  21. Antin JH, Bierer BE, Smith BR et al. Selective depletion of bone marrow T-lymphocytes with Anti-CD5 monoclonal antibodies: effective prophylaxis of graft-versus-host disease in patients with hematologic malignancies. Blood 1991; 78: 2139–2149.

    CAS  PubMed  Google Scholar 

  22. Ash RC, Casper JT, Chitambar CR et al. Successful allogeneic transplantation of T-cell-depleted bone marrow from closely HLA-matched unrelated donors. N Engl J Med 1990; 322: 485–494.

    Article  CAS  PubMed  Google Scholar 

  23. Lee SJ, Zahrieh D, Alyea EP et al. Comparison of T-cell-depleted and non-T-cell-depleted unrelated donor transplantation for hematologic diseases: clinical outcomes, quality of life, and costs. Blood 2002; 100: 2697–2702.

    Article  CAS  PubMed  Google Scholar 

  24. Marks DI, Bird JM, Vettenranta K et al. T cell-depleted unrelated donor bone marrow transplantation for acute myeloid leukemia. Biol Blood Marrow Transplant 2000; 6: 646–653.

    Article  CAS  PubMed  Google Scholar 

  25. Ho VT, Soiffer RJ . The history and future of T-cell depletion as graft-versus-host disease prophylaxis for allogeneic hematopoietic stem cell transplantation. Blood 2001; 98: 3192–3204.

    Article  CAS  PubMed  Google Scholar 

  26. Young JW, Papadopoulos EB, Cunningham I et al. T-cell depleted allogeneic bone marrow transplantation in adults with acute nonlymphocytic leukemia in first remission. Blood 1992; 79: 3380–3387.

    CAS  PubMed  Google Scholar 

  27. Nash RA, Antin JH, Karanes C et al. Phase 3 study comparing methotrexate and tacrolimus with methotrexate and cyclosporine for prophylaxis of acute graft-versus-host disease after marrow transplantation from unrelated donors. Blood 2000; 96: 2062–2068.

    CAS  PubMed  Google Scholar 

  28. Devine SM, Geller RB, Lin LB et al. The outcome of unrelated donor bone marrow transplantation in patients with hematologic malignancies using tacrolimus (FK506) and low dose methotrexate for graft-versus-host disease prophylaxis. Biol Blood Marrow Transplant 1997; 3: 25–33.

    CAS  PubMed  Google Scholar 

  29. Barker JN, Davies SM, DeFor T et al. Survival after transplantation of unrelated donor umbilical cord blood is comparable to that of human leukocyte antigen-matched unrelated donor bone marrow: results of a matched-pair analysis. Blood 2001; 97: 2957–2961.

    Article  CAS  PubMed  Google Scholar 

  30. Wagner JE, Thompson JS, Carter S et al. Impact of graft-versus-host disease (GVHD) prophylaxis on 3-year disease-free survival (DFS): results of a multi-center, randomized phase II–III trial comparing T cell depletion/cyclosporine (TCD) and methotrexate/cyclosporine (M/C) in 410 recipients of unrelated donor bone marrow (BM). Blood 2002; 100 (Suppl 1): 75a–76a (Abs. #274).

    Google Scholar 

  31. Kalaycio ME . What is the curative potential of refractory leukemia with related and unrelated allogeneic transplants?. In: Bolwell BJ (ed.). Current Controversies in Bone Marrow Transplantation. Humana Press: Totowa, NJ, 2000; pp 107–117.

    Chapter  Google Scholar 

  32. Davies SM, Kollman C, Anasetti C et al. Engraftment and survival after unrelated-donor bone marrow transplantation: a report from the national marrow donor program. Blood 2000; 96: 4096–4102.

    CAS  PubMed  Google Scholar 

  33. Mehta J, Powles RL, Mitchell P et al. Graft failure after bone marrow transplantation from unrelated donors using busulfan and cyclophosphamide for conditioning. Bone Marrow Transplant 1994; 13: 583–587.

    CAS  PubMed  Google Scholar 

  34. Topolsky D, Crilley P, Styler MJ et al. Unrelated donor bone marrow transplantation without T cell depletion using a chemotherapy only conditioning regimen. Low incidence of failed engraftment and severe acute GVHD. Bone Marrow Transplant 1996; 17: 549–554.

    CAS  PubMed  Google Scholar 

  35. Soiffer RJ, Weller E, Alyea EP et al. CD6 donor marrow T-cell depletion as the sole form of graft-versus-host disease prophylaxis in patients undergoing allogeneic bone marrow transplant from unrelated donors. J Clin Oncol 2001; 19: 1152–1159.

    Article  CAS  PubMed  Google Scholar 

  36. Petersdorf EW, Longton GM, Anasetti C et al. Association of HLA-C disparity with graft failure after marrow transplantation from unrelated donors. Blood 1997; 89: 1818–1823.

    CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to M Kalaycio.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Kalaycio, M., Rybicki, L., Pohlman, B. et al. CD8+ T-cell-depleted, matched unrelated donor, allogeneic bone marrow transplantation for advanced AML using busulfan-based preparative regimens. Bone Marrow Transplant 35, 247–252 (2005). https://doi.org/10.1038/sj.bmt.1704736

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/sj.bmt.1704736

Keywords

This article is cited by

Search

Quick links